Newsroom
Press
Releases
Press Releases
- 1.10.2022
EQRx Enters Memorandum of Understanding with CVS Health to Create Cost Savings and Improve Patient Access to Innovative Medicines
The two companies will explore opportunities for a long-term, strategic partnership spanning the CVS Health enterprise
- 1.7.2022
EQRx and Geisinger Sign Memorandum of Understanding to Provide Access to Innovative Cancer Medicines at Radically Lower Costs
Provides roadmap to commercial agreement between EQRx and Geisinger, a U.S.-based integrated delivery network
- 1.3.2022
EQRx to Present at the 40th Annual J.P. Morgan Healthcare Conference
EQRx, Inc. (Nasdaq: EQRX), announced that Melanie Nallicheri, chief executive officer, will present virtually during the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10 at 3:45 p.m. ET.
- 12.17.2021
EQRx Debuts as Publicly Traded Company to Develop and Deliver Innovative Medicines at Radically Lower Prices
Business combination with CM Life Sciences III results in approximately $1.3 billion in cash proceeds
- 12.2.2021
EQRx and CM Life Sciences III Announce Effectiveness of Form S-4 Registration Statement and Stockholder Meeting Details to Vote on Proposed Business Combination
EQRx and CM Life Sciences III Inc. (Nasdaq: CMLTU), a life science-focused special purpose acquisition company, or SPAC, announced that the U.S. Securities and Exchange Commission (“SEC”) has declared CM Life Sciences III’s registration statement on Form S-4 relating to the previously announced business combination agreement between EQRx and CM Life Sciences III effective.